1
|
Borghaei H, Ciuleanu TE, Lee JS, Pluzanski A, Caro RB, Gutierrez M, Ohe Y, Nishio M, Goldman J, Ready N, Spigel DR, Ramalingam SS, Paz-Ares LG, Gainor JF, Ahmed S, Reck M, Maio M, O'Byrne KJ, Memaj A, Nathan F, Tran P, Hellmann MD, Brahmer JR. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. Ann Oncol 2023; 34:173-185. [PMID: 36414192 DOI: 10.1016/j.annonc.2022.11.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 09/22/2022] [Accepted: 11/11/2022] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with this regimen in a large pooled patient population and assessed the effect of response on survival. PATIENTS AND METHODS Data were pooled from four studies of first-line nivolumab plus ipilimumab in advanced NSCLC (CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012). Overall survival (OS), progression-free survival (PFS), objective response rate, duration of response, and safety were assessed. Landmark analyses of OS by response status at 6 months and by tumor burden reduction in responders to nivolumab plus ipilimumab were also assessed. RESULTS In the pooled population (N = 1332) with a minimum follow-up of 29.1-58.9 months, median OS was 18.6 months, with a 3-year OS rate of 35%; median PFS was 5.4 months (3-year PFS rate, 17%). Objective response rate was 36%; median duration of response was 23.7 months, with 38% of responders having an ongoing response at 3 years. In patients with tumor programmed death-ligand 1 (PD-L1) <1%, ≥1%, 1%-49%, or ≥50%, 3-year OS rates were 30%, 38%, 30%, and 48%. Three-year OS rates were 30% and 38% in patients with squamous or non-squamous histology. Efficacy outcomes in patients aged ≥75 years were similar to the overall pooled population (median OS, 20.1 months; 3-year OS rate, 34%). In the pooled population, responders to nivolumab plus ipilimumab at 6 months had longer post-landmark OS than those with stable or progressive disease; 3-year OS rates were 66%, 22%, and 14%, respectively. Greater depth of response was associated with prolonged survival; in patients with tumor burden reduction ≥80%, 50% to <80%, or 30% to <50%, 3-year OS rates were 85%, 72%, and 44%, respectively. No new safety signals were identified in the pooled population. CONCLUSION Long-term survival benefit and durable response with nivolumab plus ipilimumab in this large patient population further support this first-line treatment option for advanced NSCLC.
Collapse
Affiliation(s)
- H Borghaei
- Hematology and Oncology Department, Fox Chase Cancer Center, Philadelphia, USA.
| | - T-E Ciuleanu
- Department of Medical Oncology, Institutul Oncologic Prof Dr Ion Chiricuta, Cluj-Napoca; Department of Medical Oncology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
| | - J-S Lee
- Department of Hematology/Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - A Pluzanski
- Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - R Bernabe Caro
- Medical Oncology Department, Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Seville, Seville, Spain
| | - M Gutierrez
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA
| | - Y Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo
| | - M Nishio
- Department of Thoracic Medical Oncology Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - J Goldman
- David Geffen School of Medicine, UCLA, Los Angeles
| | - N Ready
- Department of Medicine, Duke University School of Medicine, Durham
| | - D R Spigel
- Thoracic Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology PLCC, Nashville
| | - S S Ramalingam
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, USA
| | - L G Paz-Ares
- Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
| | - J F Gainor
- Department of Medicine, Massachusetts General Hospital, Boston, USA
| | - S Ahmed
- Department of Medical Oncology, University Hospitals of Leicester, Leicester, UK
| | - M Reck
- Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, Lung Clinic, Grosshansdorf, Germany
| | - M Maio
- Center for Immuno-Oncology, University Hospital of Siena and University of Siena, Siena, Italy
| | - K J O'Byrne
- Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia
| | - A Memaj
- Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton
| | - F Nathan
- OneClinical, Bristol Myers Squibb, Princeton
| | - P Tran
- WW Medical Oncology Department, Bristol Myers Squibb, Princeton
| | - M D Hellmann
- Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York
| | - J R Brahmer
- Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, USA
| |
Collapse
|
2
|
John T, Grohe C, Goldman J, De Marinis F, Kato T, Wang Q, Choi JH, Melotti B, Fidler M, Sainsbury L, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst R, Majem Tarruella M. LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
3
|
Smith C, Abtin F, Xiang M, Yoon S, Ruan D, Goldman J, Cummings A, Lisberg A, Garon E, Barjaktarevic I, Moghanaki D. Incidence of Radiation Pneumonitis Among Patients Treated with Concurrent Thoracic Radiotherapy and Osimertinib for Metastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
4
|
Goldman J, Martínez Bueno A, Dooms C, Jhaveri K, de Miguel M, Piha-Paul S, Unni N, Mahipal A, Suga J, Naltet C, Zick A, Antoñanzas Basa M, Crown J, Chae Y, DiPrimeo D, Eli L, McCulloch L, Mahalingam D. Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01017-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
5
|
Goldman J, Cummings A, Mendenhall M, Velez M, Babu S, Johnson T, Alcantar J, Dakhil S, Kanamori D, Lawler W, Anand S, Chauv J, Garon E, Slamon D. OA12.03 Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Goldman J, Huang H, Cummings A, Noor Z, Slomowitz S, Kirimis E, Olevsky O, Arzoo K, Ashouri S, DiCarlo B, Hu EL, Wong D, Chauv J, Garon E, Yarden Y, Slamon D. MA07.05 Phase 1b/2 Study of Combined HER Inhibition in Refractory EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
7
|
Lisberg A, Liu B, Salehi-Rad R, Lee J, Tran L, Kostyantyn K, Lim R, Dumitras C, Jing Z, Abtin F, Suh R, Genshaft S, Fishbein G, Kaul A, Kahlon K, Ashouri S, Goldman J, Elashoff D, Garon E, Dubinett S. P11.01 Phase I Trial of in Situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Pash E, Bialonczyk D, Madaghiele M, Demitri C, Goldman J, Sannino A. Unique Physical Properties of an Oral Super Absorbent Hydrogel compared to Common Fiber Supplements. J Acad Nutr Diet 2021. [DOI: 10.1016/j.jand.2021.08.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Goldman J, Moiseenko F, Cicin I, Horinouchi H, Filippova E, Bar J, Lu S, Tomasini P, Ocampo C, Sullivan D, Maag D, Motwani M, Jin J, Camidge D. P47.03 Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
10
|
Camidge D, Moiseenko F, Cicin I, Horinouchi H, Filippova E, Bar J, Lu S, Tomasini P, Ocampo C, Sullivan D, Maag D, Goldman J. OA15.04 Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.085] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Cho B, Piotrowska Z, Le X, Goldberg S, Goldman J, De Langen A, Okamoto I, Smith P, Mensi I, Maidment J, Hartmaier R, Li M, Doughton G, Patel G, Pease J, Szekeres P, Riess J, Yu H. P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1084] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Rotow J, Patel J, Hanley M, Yu H, Goldman J, Nechustan H, Scheffler M, Awad M, Clifford S, Santucci A, Silva L, Tupper R, Oxnard G, Kherani J, Drilon A. FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.150] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Reinmuth N, Garassino M, Trukhin D, Hochmair M, Özgüroğlu M, Havel L, Goldman J, Chen Y, Losonczy G, Spinnato F, Conev N, Bar J, Broadhurst H, Byrne N, Jiang H, Paz-Ares L. P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.873] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
14
|
Wu Y, John T, Grohe C, Majem M, Goldman J, Kim S, Kato T, Laktionov K, Vu H, Wang Z, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Atasoy A, Herbst R, Tsuboi M. OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.292] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
15
|
Boni V, Dooms C, Haley B, Viteri S, Mahipal A, Suga J, Eli L, Lalani A, Bryce R, Xu F, Shah N, Kabbinavar F, Goldman J. OA04.06 Neratinib in Pretreated EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Initial Findings From the SUMMIT Basket Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.286] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Goldman J. M227 WHEN CD8 ENTERS THE CSF: A RARE PRESENTATION OF CNS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
Heuer HW, Wang P, Rascovsky K, Wolf A, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber DE, Caso C, Coppola G, Dickerson B, Dickinson S, Domoto-Reilly K, Faber K, Ferrall J, Fields J, Fishman A, Fong J, Foroud T, Forsberg LK, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Hsiung GY, Huey E, Irwin D, Jones D, Kantarci K, Karydas A, Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Kraft R, Kremers WK, Kukull W, Litvan I, Ljubenkov P, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis S, McKinley E, Mendez MF, Miller BL, Onyike C, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Roberson ED, Rogalski E, Sengdy P, Shaw L, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski J, Weintraub S, Wong B, Wszolek Z, Boeve BF, Rosen HJ, Boxer AL. Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort. Alzheimers Dement 2020; 16:60-70. [PMID: 31914226 PMCID: PMC7192555 DOI: 10.1002/alz.12046] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Behavioral variant frontotemporal dementia (bvFTD) may present sporadically or due to an autosomal dominant mutation. Characterization of both forms will improve understanding of the generalizability of assessments and treatments. METHODS A total of 135 sporadic (s-bvFTD; mean age 63.3 years; 34% female) and 99 familial (f-bvFTD; mean age 59.9; 48% female) bvFTD participants were identified. f-bvFTD cases included 43 with known or presumed chromosome 9 open reading frame 72 (C9orf72) gene expansions, 28 with known or presumed microtubule-associated protein tau (MAPT) mutations, 14 with known progranulin (GRN) mutations, and 14 with a strong family history of FTD but no identified mutation. RESULTS Participants with f-bvFTD were younger and had earlier age at onset. s-bvFTD had higher total Neuropsychiatric Inventory Questionnaire (NPI-Q) scores due to more frequent endorsement of depression and irritability. DISCUSSION f-bvFTD and s-bvFTD cases are clinically similar, suggesting the generalizability of novel biomarkers, therapies, and clinical tools developed in either form to the other.
Collapse
Affiliation(s)
- Hilary W Heuer
- University of California, San Francisco, San Francisco, California
| | - P Wang
- University of California, San Francisco, San Francisco, California
| | - K Rascovsky
- University of Pennsylvania, Philadelphia, Pennsylvania
| | - A Wolf
- University of California, San Francisco, San Francisco, California
| | - B Appleby
- Case Western Reserve University, Cleveland, Ohio
| | - J Bove
- University of Pennsylvania, Philadelphia, Pennsylvania
| | - Y Bordelon
- University of California, Los Angeles, Los Angeles, California
| | - P Brannelly
- Tau Consortium, Rainwater Charitable Foundation, Fort Worth, Texas
| | | | - C Caso
- U Washington, Seattle, Washington
| | - G Coppola
- University of California, Los Angeles, Los Angeles, California
| | - B Dickerson
- Harvard University/MGH, Boston, Massachusetts
| | - S Dickinson
- Association for Frontotemporal Degeneration, Radnor, Pennsylvania
| | | | - K Faber
- National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, Indiana
| | - J Ferrall
- University of North Carolina, Chapel Hill, North Carolina
| | - J Fields
- Mayo Clinic, Rochester, Minnesota
| | - A Fishman
- Johns Hopkins University, Baltimore, Maryland
| | - J Fong
- University of California, San Francisco, San Francisco, California
| | - T Foroud
- National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, Indiana
| | | | | | | | - N Ghoshal
- Washington University, St. Louis, Missouri
| | - J Goldman
- Columbia University, New York, New York
| | | | | | - I Grant
- Northwestern University, Chicago, Illinois
| | - M Grossman
- University of Pennsylvania, Philadelphia, Pennsylvania
| | - D Haley
- Mayo Clinic, Jacksonville, Florida
| | - G-Y Hsiung
- University of British Columbia, Vancouver, British Columbia, Canada
| | - E Huey
- Columbia University, New York, New York
| | - D Irwin
- University of Pennsylvania, Philadelphia, Pennsylvania
| | - D Jones
- Mayo Clinic, Rochester, Minnesota
| | | | - A Karydas
- University of California, San Francisco, San Francisco, California
| | - D Kaufer
- University of North Carolina, Chapel Hill, North Carolina
| | - D Kerwin
- The University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas
| | | | - J Kornak
- University of California, San Francisco, San Francisco, California
| | - J H Kramer
- University of California, San Francisco, San Francisco, California
| | - R Kraft
- Mayo Clinic, Rochester, Minnesota
| | | | - W Kukull
- National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, Washington
| | - I Litvan
- University of California, San Diego, San Diego, California
| | - P Ljubenkov
- University of California, San Francisco, San Francisco, California
| | - I R Mackenzie
- University of British Columbia, Vancouver, British Columbia, Canada
| | - M Maldonado
- University of California, Los Angeles, Los Angeles, California
| | | | - S McGinnis
- Harvard University/MGH, Boston, Massachusetts
| | - E McKinley
- University of Alabama at Birmingham, Birmingham, Alabama
| | - M F Mendez
- University of California, Los Angeles, Los Angeles, California
| | - B L Miller
- University of California, San Francisco, San Francisco, California
| | - C Onyike
- Johns Hopkins University, Baltimore, Maryland
| | - A Pantelyat
- Johns Hopkins University, Baltimore, Maryland
| | - R Pearlman
- Bluefield Project, San Francisco, California
| | | | - M Potter
- National Centralized Repository for Alzheimer's Disease and Related Disorders (NCRAD), Indiana University, Indianapolis, Indiana
| | | | - E M Ramos
- University of California, Los Angeles, Los Angeles, California
| | - K P Rankin
- University of California, San Francisco, San Francisco, California
| | - E D Roberson
- University of Alabama at Birmingham, Birmingham, Alabama
| | - E Rogalski
- Northwestern University, Chicago, Illinois
| | - P Sengdy
- University of British Columbia, Vancouver, British Columbia, Canada
| | - L Shaw
- University of Pennsylvania, Philadelphia, Pennsylvania
| | | | | | - N Tatton
- Association for Frontotemporal Degeneration, Radnor, Pennsylvania
| | - J Taylor
- University of California, San Francisco, San Francisco, California
| | - A Toga
- Laboratory of Neuroimaging (LONI), USC, Los Angeles, California
| | | | | | - B Wong
- Harvard University/MGH, Boston, Massachusetts
| | | | | | - H J Rosen
- University of California, San Francisco, San Francisco, California
| | - A L Boxer
- University of California, San Francisco, San Francisco, California
| |
Collapse
|
18
|
Cummings A, Goldman J, Mendenhall M, Kanamori D, Nguyen A, Kim D, Wainberg Z. P2.12-09 Phase 2 Study of Talazoparib Plus Low-Dose Temozolomide in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Camidge D, Barlesi F, Goldman J, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su W, Hong D, Strickler J, Motwani M, Sun Z, Parikh A, Komarnitsky P, Wu J, Kelly K. MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.612] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair M, Özgüroğlu M, Ji J, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev N, Armstrong J, Byrne N, Shire N, Jiang H, Goldman J. PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.061] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
21
|
Lee P, Luterstein E, Goldman J, Garon E, Lee J, Felix C, Cao M, Tenn S, Low D, Kupelian P, Steinberg M. Accelerated Hypofractionated CRT Followed by SABR Boost (HyCRT-SABR) for Locally Advanced Unresectable NSCLC: A Prospective Phase II Radiation Dose-Escalation Study. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.469] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Garon E, Wong D, Schneider J, Aljumaily R, Korn W, Patel M, Autio K, Papadopoulos K, Naing A, Gabrail N, Munster P, Goldman J, Hung A, Oft M, Leveque J, Spigel D. Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Camidge R, Heist R, Goldman J, Angevin E, Strickler J, Morgensztern D, Barve M, Bauer T, Vokes E, Yi T, Motwani M, Parikh A, Wu J, Kelly K. An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
24
|
Fanelli Kuczmarski M, Sebastian R, Steinfeldt L, Goldman J, Murayi T, Moshfegh A, Zonderman A, Evans M. Flavonoid Intakes of Urban African American and White Adults. J Acad Nutr Diet 2018. [DOI: 10.1016/j.jand.2018.06.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
25
|
Hoy M, Goldman J, Steinfeldt L, Moshfegh A. Comparison of Weight Loss Approaches Used by Adults by Weight Loss Status. J Acad Nutr Diet 2018. [DOI: 10.1016/j.jand.2018.06.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
26
|
Rabe L, Goldman J, Bracken S, Juul J, Meyn L, Hillier S. Prevalence of candida africana among women with Vulvovaginal Candidiasis (VVC) and/or Bacterial Vaginosis (BV) in the United States. Am J Obstet Gynecol 2017. [DOI: 10.1016/j.ajog.2017.08.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Wong D, Schneider J, Aljumaily R, Korn W, Infante J, Patel M, Autio K, Papadopoulos K, Naing A, Gabrail N, Munster P, Goldman J, Ratti N, Van Vlasselaer P, Hung A, Oft M, Garon E. PEGylated human IL-10 (AM0010) in combination with an anti-PD-1 in advanced NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Goldman J, Angevin E, Strickler J, Camidge D, Heist R, Morgensztern D, Barve M, Yue H, Beaulieu J, Motwani M, Afar D, Naumovski L, Kelly K. MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.458] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Langer C, Anderson E, Jotte R, Goldman J, Haggstrom D, Modiano M, Socoteanu M, Smith D, Dahkil C, Konduri K, Kim E, Sanford A, Amiri K, Weiss J. Quality of life (QoL) in elderly NSCLC patients (pts) treated with nab-paclitaxel/carboplatin (nab-P/C) in the ABOUND.70+ trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Garrido Lopez P, Goldman J, Kelly K, Kim E, Beck T, Alonso Garcia M, Yang Z, Ingram KJ, Amstutz L, John W, Provencio Pulla M. Efficacy and safety of abemaciclib combined with either LY3023414 or pembrolizumab in stage IV NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Wong D, Schneider J, Aljumaily R, Korn M, Autio K, Infante J, Patel M, Papadopoulos K, Naing A, Gabrail N, Munster P, Goldman J, Van Vlasselaer P, Hung A, Brown G, Oft M, Garon E. Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Piotrowska Z, Liu E, Varga A, Thakur M, Narayanan V, Liu S, Neal J, Spiegel M, Solomon B, Yu H, Ou SH, Papadimitrakopoulou V, Gadgeel S, Camidge D, Soria JC, Wakelee H, Goldman J, Kopani K, Rolfe L, Sequist L. Rociletinib-associated cataracts in EGFR-mutant NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Weiss J, Kim E, Amiri K, Anderson E, Dakhil S, Haggstrom D, Jotte R, Konduri K, Modiano M, Ong T, Sanford A, Smith D, Socoteanu M, Goldman J, Langer C. Quality of life (QoL) in elderly patients (pts) with advanced NSCLC treated with nab-paclitaxel (nab-P) + carboplatin (C): Interim results from the ABOUND.70+ study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.81] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Gettinger S, Hellmann M, Shepherd F, Antonia S, Brahmer J, Chow L, Goldman J, Juergens R, Borghaei H, Ready N, Gerber D, Nathan F, Shen Y, Harbison C, Rizvi N. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31737-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Goldman J, Belani C, Novello S, von Pawel J, Csoszi T, Orlov S, Kroll S, Pearce T. Randomized, Double-Blind, Placebo-Controlled Trial of Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.46] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Sikorsky N, Schneider V, Goldman J, Leviov M, Leitzin L, Keren S, Steiner M. P294 Breast biopsies during follow up after intraoperative radiotherapy in early breast cancer patients. Breast 2015. [DOI: 10.1016/s0960-9776(15)70326-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
37
|
Soria JC, Sequist L, Goldman J, Wakelee H, Neal J, Camidge R, Gadgeel S, Papadimitrakopoulou V, Dziadziuszko R, Piotrowska Z, Varga A, Solomon B. Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv088.3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Aghion E, Jan L, Meshi L, Goldman J. Increased corrosion resistance of the AZ80 magnesium alloy by rapid solidification. J Biomed Mater Res B Appl Biomater 2014; 103:1541-8. [PMID: 25491147 DOI: 10.1002/jbm.b.33335] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2014] [Revised: 10/06/2014] [Accepted: 11/04/2014] [Indexed: 12/26/2022]
Abstract
Magnesium (Mg) and Mg-alloys are being considered as implantable biometals. Despite their excellent biocompatibility and good mechanical properties, their rapid corrosion is a major impediment precluding their widespread acceptance as implantable biomaterials. Here, we investigate the potential for rapid solidification to increase the corrosion resistance of Mg alloys. To this end, the effect of rapid solidification on the environmental and stress corrosion behavior of the AZ80 Mg alloy vs. its conventionally cast counterpart was evaluated in simulated physiological electrolytes. The microstructural characteristics were examined by optical microscopy, SEM, TEM, and X-ray diffraction analysis. The corrosion behavior was evaluated by immersion, salt spraying, and potentiodynamic polarization. Stress corrosion resistance was assessed by Slow Strain Rate Testing. The results indicate that the corrosion resistance of rapidly solidified ribbons is significantly improved relative to the conventional cast alloy due to the increased Al content dissolved in the α-Mg matrix and the correspondingly reduced presence of the β-phase (Mg17 Al12 ). Unfortunately, extrusion consolidated solidified ribbons exhibited a substantial reduction in the environmental performance and stress corrosion resistance. This was mainly attributed to the detrimental effect of the extrusion process, which enriched the iron impurities and increased the internal stresses by imposing a higher dislocation density. In terms of immersion tests, the average corrosion rate of the rapidly solidified ribbons was <0.4 mm/year compared with ∼2 mm/year for the conventionally cast alloy and 26 mm/year for the rapidly solidified extruded ribbons.
Collapse
Affiliation(s)
- E Aghion
- Department of Materials Engineering, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel
| | - L Jan
- Department of Materials Engineering, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel
| | - L Meshi
- Department of Materials Engineering, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel
| | - J Goldman
- Biomedical Engineering Department, Michigan Technological University, Houghton, Michigan, 49931
| |
Collapse
|
39
|
Rosen L, Goldman J, Hubbard J, Roos M, Capdevila J, Maynes J, Lin W, O'Keeffe B, Lackner M, Spoerke J, Ware J, Arnieri B, Freas E, Leong S. 382 Phase Ib study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6 + bevacizumab in patients with advanced solid tumors and colorectal cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70508-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Rizvi N, Shepherd F, Antonia S, Brahmer J, Chow L, Goldman J, Juergens R, Borghaei H, Ready N, Gerber D, Shen Y, Harbison C, Chen A, Gettinger S. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.08.204] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
41
|
Gettinger S, Rizvi N, Chow L, Borghaei H, Brahmer J, Juergens R, Shepherd F, Laurie S, Gerber D, Goldman J, Shen Y, Harbison C, Chen A, Antonia S. Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu342.7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Zhao B, Tan Y, Tsai W, Lu L, Schwartz L, Lu Z, So J, Goldman J. TU-A-12A-07: CT-Based Biomarkers to Characterize Lung Lesion: Effects of CT Dose, Slice Thickness and Reconstruction Algorithm Based Upon a Phantom Study. Med Phys 2014. [DOI: 10.1118/1.4889253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
43
|
Goldman J. An ethical price tag?: The case of cancer drugs. Eur J Public Health 2013. [DOI: 10.1093/eurpub/ckt126.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
44
|
Pool C, Shankar G, Schantz A, Gunn G, Bolce R, Leirisalo-Repo M, Wang J, Goldman J, DeHoratius R, Fleischmann R, Decktor D. THU0181 Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes after an Active Switch to Infliximab. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Falchook G, Zhou X, Rosen L, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman J, Jung J, Milch C, Sarantopoulos J. Food Effect Study of the Investigational Aurora a Kinase (AAK) Inhibitor MLN8237 (ALISERTIB) in Patients with Advanced Solid Tumors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33051-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
46
|
Rosen L, Goldman J, Stewart S, Hubbard J, Roos M, Lin W, Shankar G, Capdevila J, Freas E, Leong S. A Phase 1B Study to Evaluate the Safety and Pharmacology of the Dual PI3K-MTOR Inhibitor GDC-0980 in Combination with a Fluoropyrimidine, Oxaliplatin, and Bevacizumab (BEV) in Patients with Advanced Solid Tumors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33010-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
47
|
Ghode R, Ouyang B, Bernard B, Stebbins G, Goldman J. Excessive Daytime Sleepiness, Sleep Quality, and Cognitive Impairment in Parkinson's Disease (P06.053). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p06.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
48
|
Barton B, Bernard B, Stebbins G, Goldman J, Dubois B, Goetz C. Comparison of Movement Disorder Society Criteria for Parkinson's Disease Dementia with Routine Clinical Neuropsychological Testing (PD4.006). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.pd4.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
49
|
Goldman J, Bernard R, Bernard B, Stebbins G. Comparison of Clock Scoring Methods in Detecting Mild Cognitive Impairment and Dementia in Parkinson's Disease (PD4.008). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.pd4.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
50
|
Abstract
The neurosurgical literature contains little information about the current management of patients with thyroid-stimulating hormone (TSH)-secreting pituitary adenomas or about the usefulness of the somatostatin analogue octreotide in such cases. While TSH-secreting pituitary adenomas are rare, our review and illustrative case demonstrate the effectiveness of pretreating patients with octreotide therapy not only to reduce tumor size prior to surgical resection but also to increase the possibility of clinical remission.A 52-year-old male presented with signs and symptoms of hyperthyroidism and elevated TSH, thyroxine, and triiodothyronine. Magnetic resonance imaging revealed a pituitary macroadenoma with extension into the suprasellar cistern. The patient was treated with octreotide for 6 months prior to surgery. Approximately 3 months after initiation of octreotide therapy, the patient exhibited excellent biochemical and clinical response. Tumor shrinkage of nearly 50% was associated with resolution of suprasellar extension and optic nerve compression. Subsequent transsphenoidal surgery for resection of residual adenoma was followed by symptomatic and hormonal remission without the need for reinstitution of octreotide therapy.Pretreatment with octreotide for TSH-secreting pituitary adenomas has a beneficial effect on disease symptoms and reduces tumor mass. We suggest that patients with these rare tumors can be managed with a combination of octreotide therapy and subsequent surgical removal of residual tumor. Although this combination treatment helps to facilitate clinical remission, only short-term follow-up has been reported and thus the optimal management of these patients remains to be determined.
Collapse
|